Reaction
Malignant Transformation reporting signals
As of the last recalculation, Malignant Transformation appears in 443 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 432.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Gefitinib | 70 | 432.5 | 435.9 |
| Osimertinib | 116 | 230.0 | 230.8 |
| Melphalan | 85 | 217.0 | 217.8 |
| Melphalan Hydrochloride | 85 | 196.9 | 197.5 |
| Ifosfamide | 57 | 142.9 | 143.3 |
| Etoposide | 138 | 127.6 | 127.9 |
| Erlotinib | 23 | 117.6 | 117.9 |
| Erlotinib Hydrochloride | 24 | 95.2 | 95.4 |
| Cytarabine | 86 | 83.2 | 83.3 |
| Pemetrexed | 31 | 73.0 | 73.1 |
| Cisplatin | 73 | 52.4 | 52.4 |
| Bleomycin Sulfate | 10 | 46.5 | 46.6 |
| Fludarabine Phosphate | 32 | 41.1 | 41.2 |
| Pemetrexed Disodium | 31 | 41.0 | 41.1 |
| Doxorubicin | 51 | 30.3 | 30.3 |
| Carboplatin | 51 | 21.2 | 21.2 |
| Polatuzumab Vedotin | 4 | 19.4 | 19.4 |
| Obinutuzumab | 6 | 17.4 | 17.4 |
| Durvalumab | 7 | 16.4 | 16.4 |
| Acalabrutinib | 4 | 15.6 | 15.6 |
| Leuprolide Acetate | 23 | 14.6 | 14.6 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 10.8 | 10.8 |